Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.4.0.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash Flows from Operating Activities:    
Net Loss $ (16,643) $ (12,535)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation expense 4 6
Noncash interest expense 0 188
Amortization of debt discount 369 0
Stock-based compensation expense 2,866 1,470
Issuance of subsidiaries' common shares for license expenses 48 513
Change in fair value of investments 918 215
Change in fair value of subsidiary's warrant liabilities 89 0
Research and development-licenses acquired, expense 35 6,929
Unrealized gain on marketable securities 0 (2)
Realized gain on marketable securities 0 (1)
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:    
Other receivables - related party (1,158) 0
Prepaid expenses and other current assets (166) 22
Accounts payable and accrued expenses 169 1,853
Interest payable 0 (2)
Other 0 (61)
Other long-term liabilities 1,832 (500)
Net cash used in operating activities (11,637) (1,905)
Cash Flows from Investing Activities:    
Purchase of research and development licenses (35) (6,929)
Purchase of property and equipment (2,293) 0
Purchase of license (200) (1,250)
Payment to related parties - CB Pharma Acquisition Corp (175) (108)
Net cash used in investing activities (2,703) (8,287)
Cash Flows from Financing Activities:    
Proceeds from exercise of stock options 0 216
Proceeds from subsidiary's offering - related party 570 0
Payment of costs related to subsidiary's offering (205) 0
Payment of NSC note (2,792) 0
Proceeds from NSC note 0 10,000
Payment of debt issue costs associated with NSC Note 0 (855)
Net cash (used in) provided by financing activities (2,427) 9,361
Net decrease in cash and cash equivalents (16,767) (831)
Cash and cash equivalents at beginning of period 98,182 49,759
Cash and cash equivalents at end of period 81,415 48,928
Supplemental disclosure of cash flow information:    
Cash paid for interest 77 80
Supplemental disclosure of non-cash financing and investing activities:    
Issuance of restricted stock $ 2 $ 1